Table 4 Summary statistics of the BASMI₂, BASMI₁₀, and BASMI_lin for the various patient groups used to evaluate the status scores and the change over a 24-week treatment period with either placebo or active treatment

	Patients (n)	Assessments (n)	Treatment	BASMI₂	BASMI₁₀	BASMI_lin
Status score OASIS	443	598	NA	3.6 (2.2) (0–10)/3 (2;5)	4.2 (1.7) (1–9.2)/4 (2.8;5.4)	4.1 (1.7) (0.5–9.2)/4.1 (2.8;5.3)
Baseline score trials	63	63	Placebo	4.3 (2.2) (0–9)/4 (3;6)	4.7 (2.2) (1–8.8)/4,8 (3.2;5.8)	4.8 (1.7) (1.2–9)/4.8 (3.3;5.9)
Baseline score trials	159	159	Active*	4.3 (2.2) (0–10)/4 (2;6)	4.7 (1.7) (1–9.2)/4.6 (3.6;6)	4.7 (1.6) (1.1–9.2)/4.6 (3.7;5.9)
Change score 24 weeks	63	63	Placebo	−0.14 (0.9) (−2–2)/0 (−1;0)	−0.19 (0.59)(−1.8–1)/−0.2 (−0.6;0.2)	−0.19 (0.54) (−1.68–0.88)/−0.17 (−0.54;0.16)
Change score 24 weeks	159	159	Active*	−0.59 (1.3) (−5–3)/−1 (−1;0)	−0.56 (0.9) (−4–2.6)/−0.6 (−1.2;0)	−0.56 (0.89) (−4–2.4)/−0.57 (−1.06;−0.32)

*One of the TNF blockers infliximab, adalimumab, or etanercept.
Data are presented as mean (SD) (range)/median (p25, p75).
BASMI, Bath Ankylosing Spondylitis Metrology Index; OASIS, Outcome in Ankylosing Spondylitis International Study; TNF, tumour necrosis factor.